Regeneron Pharmaceuticals Share Repurchase Program, Remaining Authorized, Amount decreased by 68.1% to $688.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 82.2%, from $3.87B to $688.20M. This decline may warrant attention — for this metric, higher values are generally preferred.
A high remaining balance indicates potential future support for the stock price through buybacks.
This is the portion of the board-authorized share repurchase program that has not yet been executed. It indicates the re...
Used by investors to gauge the near-term potential for share count reduction and capital return.
other_stock_repurchase_program_remaining_authorized_repu_889179| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.05B | $2.33B | $1.83B | $1.23B | $3.63B | $2.89B | $3.87B | $2.81B | $2.16B | $688.20M |
| QoQ Change | — | -23.6% | -21.7% | -32.5% | +194.5% | -20.3% | +33.9% | -27.4% | -23.4% | -68.1% |
| YoY Change | — | — | — | -59.6% | +55.7% | +58.4% | +214.2% | -22.5% | -25.5% | -82.2% |